Abstract:Abstract Background Histone lysine-specific demethylase 1 (LSD1) expression has been shown to be significantly elevated in gastric cancer (GC) and may be associated with the proliferation and metastasis of GC. It has been reported that LSD1 repressed tumor immunity through programmed cell death 1 ligand 1 (PD-L1) in melanoma and breast cancer. The role of LSD1 in the immune microenvironment of GC is unknown. Methods Expression LSD1 and PD-L1 in GC patients was analyzed by immunohistochemical (IHC) and Western blotting. Exosomes were isolated from the culture medium of GC cells using an ultracentrifugation method and characterized by transmission electronic microscopy (TEM), nanoparticle tracking analysis (NTA), sucrose gradient centrifugation, and Western blotting. The role of exosomal PD-L1 in T-cell dysfunction was assessed by flow cytometry, T-cell killing and enzyme-linked immunosorbent assay (ELISA). Results Through in vivo exploration, mouse forestomach carcinoma (MFC) cells with LSD1 knockout (KO) showed significantly slow growth in 615 mice than T-cell-deficient BALB/c nude mice. Meanwhile, in GC specimens, expression of LSD1 was negatively correlated with that of CD8 and positively correlated with that of PD-L1. Further study showed that LSD1 inhibited the response of T cells in the microenvironment of GC by inducing the accumulation of PD-L1 in exosomes, while the membrane PD-L1 stayed constant in GC cells. Using exosomes as vehicles, LSD1 also obstructed T-cell response of other cancer cells while LSD1 deletion rescued T-cell function. It was found that while relying on the existence of LSD1 in donor cells, exosomes can regulate MFC cells proliferation with distinct roles depending on exosomal PD-L1-mediated T-cell immunity in vivo. Conclusion LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in GC; this finding indicates a new mechanism with which LSD1 may regulate cancer immunity in GC and provides a new target for immunotherapy against GC.

LSD1 inhibits the invasion and migration of breast cancer through exosomes

LSD1 modulates the bone metastasis of breast cancer cells through hnRNPA2B1-mediated sorting of exosomal miRNAs

Exosomes from LSD1 Knockdown Breast Cancer Cells Activate Osteoclastogenesis and Inhibit Osteoblastogenesis.

LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer

Lysine-specific Demethylase 1 Mediates Epidermal Growth Factor Signaling to Promote Cell Migration in Ovarian Cancer Cells

LSD1 Knockdown Reveals Novel Histone Lysine Methylation in Human Breast Cancer MCF-7 Cells

LSD1-mediated Epigenetic Modification Contributes to Ovarian Cancer Cell Migration and Invasion.

Over-Expression of Lsd1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer

The E239K mutation abolishes the suppressive effects of LSD1 on the migration and invasion of MCF7 cells

LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9

The R251Q Mutation of LSD1 Promotes Invasion and Migration of Luminal Breast Cancer Cells.

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

E239K Mutation Abolishes the Suppressive Effects of Lysine-Specific Demethylase 1 on Migration and Invasion of MCF7 Cells.

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression

LSD1 is a promising target to treat cancers by modulating cell stemness

LSD1 Sustains Pancreatic Cancer Growth Via Maintaining HIF1α-dependent Glycolytic Process

Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms

LSD1 Silencing Contributes to Enhanced Efficacy of Anti-Cd47/pd-l1 Immunotherapy in Cervical Cancer.

Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment